Sanofi set to spin off API business late next year - report

Sanofi is to begin preparations in autumn to spin off its active ingredients business and is lining up a potential stock market launch by 2022, according to a press report. 

Gilead working with generics firms to boost global supply of...

Gilead has outlined plans to work with generics firms to rapidly increase production of its COVID-19 drug remdesivir to meet global demand. 

Coronavirus has caused drug shortage, says FDA chief

The FDA has announced the first drug shortage caused by the COVID-19 coronavirus outbreak, following previous warnings about its impact on the drug supply chain.

COVID-19 could disrupt supplies of cheap generics, analysts ...

An extended COVID-19 coronavirus outbreak could impact on supplies of generic drugs that many health systems rely on to keep costs as low as possible, according to a new report from ratings

Novartis taps Amazon know-how for ‘smart’ manufacturing, sup...

Sanofi opens digital biologics manufacturing site

Sanofi has opened a manufacturing facility in the US, one of the world’s first facilities using digital continuous biologics production technology.